Australia markets closed
  • ALL ORDS

    6,816.80
    -32.00 (-0.47%)
     
  • ASX 200

    6,601.10
    -35.30 (-0.53%)
     
  • AUD/USD

    0.7376
    +0.0019 (+0.26%)
     
  • OIL

    45.33
    -0.38 (-0.83%)
     
  • GOLD

    1,810.90
    -0.30 (-0.02%)
     
  • BTC-AUD

    22,904.22
    -430.49 (-1.84%)
     
  • CMC Crypto 200

    330.38
    -40.13 (-10.83%)
     
  • AUD/EUR

    0.6183
    +0.0010 (+0.17%)
     
  • AUD/NZD

    1.0504
    +0.0001 (+0.01%)
     
  • NZX 50

    12,639.83
    +37.81 (+0.30%)
     
  • NASDAQ

    12,152.21
    +72.41 (+0.60%)
     
  • FTSE

    6,332.86
    -30.07 (-0.47%)
     
  • Dow Jones

    29,872.47
    -173.77 (-0.58%)
     
  • DAX

    13,321.52
    +34.95 (+0.26%)
     
  • Hang Seng

    26,894.68
    +75.23 (+0.28%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     

Anatara Lifesciences Ltd (ANR.AX) Quarterly Financial Report

·2-min read
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ANR.AX) Quarterly Financial Report

Brisbane, Australia, Oct 28, 2020 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2020. The Company's cash plus term deposits at the end of the quarter stood at $1.59m (30th June 2020: $2.7m). On 30th September 2020, the Company had cash at bank of $1.09m and $0.5m in term deposits.

Net cash outflow during the quarter was 74% higher than the prior quarter due to initiation of the GaRP clinical trial. Continued cash preservation initiatives drove quarterly reductions in staff costs by 17% (-44% on Quarter September 2019) and administration and corporate costs by 5% (-40% on Quarter September 2019).

Aggregate amount of payments to related parties and their associates during the quarter was $85,000 which includes directors' fees and superannuation.

Forecast cash outflow for the December 2020 quarter is anticipated to decrease in comparison to the September 2020 quarter which contained significant upfront costs associated with initiation of the GaRP clinical trial. Anatara also anticipates receipt of an R&D Tax Incentive refund during the December 2020 quarter of $612,967.

Anatara announced during the quarter: (1) initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf); (2) investor presentation made to the ASX Small and Mid-Cap Conference 2020.

CEO Steve Lydeamore commented, "Anatara is pleased to have successfully completed a placement to progress a clinical study of Anatara's GaRP in irritable bowel syndrome (IBS). In parallel with execution of its human health development plans, the Company has prioritised removing barriers to out-licensing Detach(R) through progression of challenge trials for newly developed formulations for piglets in-feed) and for poultry. The Company anticipates renewed interest in partnering Detach(R) upon successful completion of challenge trials."

To view the report, please visit:
https://abnnewswire.net/lnk/06GG0LR1


About Anatara Lifesciences Ltd:


Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

Contact:

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com

Source:
Anatara Lifesciences Ltd

Copyright (C) 2020 ABN Newswire. All rights reserved.